NEOPLASIA Part 2

(Characters of benign and malignant tumors)

Dr Ahmed Roshdi, PhD

Associate Prof of Pathology, Faculty of Medicine, Sohag University

Outlines

- Morphology (structure) of benign and malignant tumors.
- Behaviour of benign and malignant tumors.
- Grading and staging of malignant tumors.
- Complications of benign and malignant tumors (effects on the host).
- Causes of death in malignant tumors.
- Differences between benign and malignant tumors

Morphology (structure) of benign and malignant tumors

I. Gross appearance

Size, shape, surface, consistency, cut section and color

- ➤ Tumor cells (parenchyma)
 - Growth pattern
 - Cellular features
- >Tumor stroma
- >Tumor vasculature

I. Gross appearance

- Benign tumors: commonly appears as
 - Mass
 Polyp

 Describe size, shape, surface and cut section

- Malignant tumors: could appears as
 - Mass Describe size, shape, surface and cut section
 - Polypoid (cauliflower) Describe size, shape, surface and cut section
 - Ulcer Describe size, edge, base and floor
 - Annular In hollow organs: thick wall and narrow lumen


- Tumor cells (parenchyma): The proliferating cells
 - A. Growth pattern (low power).
 - B. Cellular features (high power).
- Tumor stroma
- Tumor vasculature

II. Microscopic features


• Tumor cells (parenchyma): The proliferating cells

A.Growth pattern


1. Epithelial tumors:




- Tumor cells (parenchyma): The proliferating cells
 - A. Growth pattern
 - 2. Mesenchymal tumors:



Bundles



Whorl



Diffuse


- Tumor cells (parenchyma): The proliferating cells
 - A. Growth pattern
 - **B.** Cellular features
 - a. Differentiation:
 - To what extent the neoplastic cells resemble native cells
 - In benign tumors; the neoplastic cells closely resemble the native cells (well-differentiated)
 - In malignant tumors: the neoplastic cells have a wide range of differentiation from well-differentiated to undifferentiated cells (anaplastic).
 - **Anaplasia**: Means complete loss of differentiation

- Tumor cells (parenchyma): The proliferating cells
 - A. Growth pattern
 - **B.** Cellular features
 - b. Cellular criteria of malignancy:
 - Loss of polarity
 - Pleomorphism
 - Hyperchromatism
 - High nucleo-cytoplasmic (N/C) ratio
 - Prominent nucleoli
 - High mitotic rates
 - Abnormal mitotic figures
 - Tumor giant cells


- Tumor cells (parenchyma): The proliferating cells
 - A. Growth pattern
 - **B.** Cellular features
 - b. Cellular criteria of malignancy:




Loss of polarity



High N/C ratio



Mitosis & prominent nucleoli



Tumor giant cells

- Tumor stroma.
 - Fibro-collagenous or connective tissue material between individual tumor cells (in mesenchymal tumors) or between groups of tumor cells (in epithelial tumor).
 - May be absent or scanty as in lymphoma and sarcoma
 - May be abundant (desmoplastic) as in carcinomas
 - Evoked by basic fibroblast growth factor (b-FGF)
- <u>Tumor vasculature</u>: Tumor cells stimulate angiogenesis of its own blood vessels by secretion of angiogenic factors or using chemokines secreted by inflammatory cells.

Behaviour of benign and malignant tumors

Behaviour of tumors

I. Rate and mode of growth

a.Benign tumors:

- Slow rate of growth
- Grow by expansion
- Some benign tumor are hormone dependent; so they can grow fast or regress based on hormone availability (as uterine leiomyoma)
- The tumor may regress due to insufficient vascular supply

b.Malignant tumors:

- Grow rapidly
- Grow by <u>infiltration</u> of surrounding tissues
- Growth rate may exceed blood supply; so tumor necrosis occurs
- Poorly differentiated tumor grow faster than better differentiated tumors

Behaviour of tumors

II. Local invasion (direct spread)

a.Benign tumors:

- Do not infiltrate adjacent tissues
- Usually has a capsule or a pseudo capsule separates it from surrounding tissues

b.Malignant tumors:

- Usually infiltrate surrounding tissues
- Non capsulated
- Have ill-defined infiltrative borders.
- Well-differentiated tumors may look capsulated (e.g. follicular thyroid carcinoma), however invasion to adjacent tissues can be detected microscopically.

Behaviour of tumors

III. Distant spread (metastasis)


- Means: migration of tumour cells to organ or site away from primary site with formation of secondary tumour masses.
- It is the single sure sign of malignancy
- Benign tumors don't metastasize but malignant tumors do.
- Some malignant tumors infiltrate adjacent tissues but have no ability to metastasize (called <u>locally malignant tumors</u>).
- Poorly differentiated tumors are more likely to metastasize compared to well-differentiated tumours
- About 1/3 of the tumors are metastastic at time of diagnosis

Grading and staging of malignant tumors

- Grading and staging are two methods to evaluate tumor severity
- They are very important for clinicians to standardize, plan and organize patients' treatment.

A. Grading

- Based on <u>degree of differentiation and number of mitosis</u>.
- Cancer may be classified as -Grade I: well-differentiated
 - -Grade II: Moderately differentiated
 - -Grade III: poorly differentiated
 - -Grade IV: undifferentiated or anaplastic
- Higher-grade tumors are aggressive than lower grade ones.
- Of note that within the same tumor, cells have different stages of differentiation. The final grade of a tumor depends on percentage of the dominant cells.



B. Staging

- Based on <u>anatomic extent of the tumor</u>,
 i.e. <u>size</u> and degree of <u>local</u> and <u>distant</u> spread of the
 - tumor
- Can be evaluated clinically, radiologically or surgically

B.Staging

- The commonly used is **TNM** staging system:
 - T: refers to primary tumor, and classified to T1, T2, T3 and T4 based on tumour size and extent of local spread
 - ➤ N: refers to <u>lymph node</u> spread and classified to N0, N1, N2 and N3 based on the number of involved LNs
 - > M: refers to distant metastasis, and classified to M0 and M1 refer to absence or presence of metastasis, respectively
- Staging is related to behaviour and prognosis of tumors:
 - Tumor confined entirely within an organ can be cured surgically.
 - Local or distant spread worsens the prognosis.

Complications: Effects of benign and malignant tumors on the host

- Complications of <u>benign</u> tumors:
 - Usually few and mostly insignificant
 - A benign tumour can be dangerous if:
 - Hormone-producing: pituitary adenoma, thyroid adenoma or pheochromocytoma.
 - Arise in, and obstruct a hollow organ:
 - Oesopagus: dysphagia
 - Intestine: intestinal obstruction
 - Bile duct: obstructive jaundice
 - Arise in vital organ:
 - vertebral column → paraplegia
 - brain tumours (glioma and meningioma)→ increased intracranial tension.
 - Malignant change: featured by increased rat of growth, infiltrate nearby structures, cellular features of malignancy and metastasis.

- Complications of <u>malignant</u> tumors:
 - Common and usually serious
 - •Include:
 - 1. Infiltration of the surrounding tissues
 - 2. Spread to distant organs (**metastasis**): commonly to Lymph nodes, Lung, Liver, Bone and Brain.
 - 3. Recurrence after surgical removal
 - 4. Obstruction: common in tumors arising in hollow organs.
 - 5. Pressure symptoms: as increased intracranial tension or obstructive jaundice
 - 6. Ulceration & hemorrhage: common in tumors of surface epithelium

- 7. Repeated secondary bacterial infection.
- 8. Anemia: due to repeated hemorrhage, bone marrow involvement or malnutrition
- 9. Persistent pain: in primary sites and bone pain in metastatic tumours.
- 10.Secondary amyloidosis: in certain tumors as multiple myeloma and medullary thyroid carcinoma.

11. Malignant cachexia:

- Means marked weakness, wasting and weight loss.
- Caused by chronic anemia, malnutrition, repeated infection, toxemia and organ failure.
- Release of tumor necrosis factor (TNF) & Interleukin play important role in pathogenesis.

12.Para-neoplastic syndromes:

- Means: Symptoms and signs caused by abnormal products of tumor cells but not by local effects of the tumor
- Examples:
 - Endocrine effects: e.g.
 - Bronchogenic carcinoma and pancreatic carcinoma →
 ACTH → Cushing syndrome
 - Carcinoid tumour of appendix and bronchial adenoma → serotonin and bradykinin → carcinoid syndrome
 - Pheochromocytoma → epinephrine and norepinephrine → hypertension
 - *Neuropathic effect*: pulmonary, gastric, and breast tumours may be accompanied with progressive neuron destruction leading to neurological symptoms.

Causes of death in malignant tumors

1. Organ failure

- Local organ failure due to direct infiltration
- Distant organ failure due to metastasis (hepatic or respiratory failure).

2. Obstruction of hollow organ

- Intestinal obstruction
- Ureteric obstruction leading to renal failure
- Obstructive jaundice leading to liver cell failure
- 3. Involvement of CNS by primary or secondary tumours.
- 4. Malnutrition: due to loss of appetite or mal-absorption

- Causes of death in malignant tumors
 - 5. Anemia, caused by:
 - Malnutrition
 - Metastasis in bone marrow
 - Ulceration and bleeding by the tumour
 - Folic acid or iron deficiency caused by high tumour cell metabolism

- 6. Malignant cachexia (see before)
- 7. Paraneoplastic syndrome (see before)

• Differences between benign and malignant tumors

Item	Benign	Malignant
Rate of growth	Usually slow	Usually rapid
Mode of growth	Expansion	Infiltration
Gross features		
• Outlines	Defined	Irregular/ill-defined
• Capsule	Usually capsulated	Non capsulated
• Size	Variable	Variable
 Consistency 	Soft to firm	Firm to hard
 Hemorrhage 	Very rare or absent	Common
 Necrosis 	Very rare or absent	Common
 Ulceration 	Very rare or absent	Common
 Surrounding tissue 	Compressed	Infiltrated

Differences between benign and malignant tumors

Item	Benign	Malignant
Microscopic features		
 Differentiation 	Well-differentiated	Variably differentiated
 Features of 	Absent	Often present

malignancy Usually preserved Usually disrupted Cellular function


Absent

Excellent; only

local complications

Metastasis

Prognosis



Frequently detected

Bad and fatal due to

metastasis

Good luck

Dr. Ahmed Roshdi